2 not yet recruiting, 2 recruiting, 1 active not recruiting. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Not yet recruiting 2, Recruiting 2, Active not recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow dalpiciclib: new trials by email Literature Review of dalpiciclib trials Research Report on dalpiciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer Fulvestrant, Pyrotinib, Dalpiciclib - Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 226 | 2026-11-01 | 2026-10-23 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
| Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment dalpiciclib + capecitabine + endocrine therapy, dalpiciclib + endocrine therapy - Breast Cancer | Phase 3 | Recruiting | Fujian Cancer Hospital | 258 | 2025-11-15 | 2026-03-12 |
| A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. JS105, Dalpiciclib, Fulvestrant 50 Mg/mL Intramuscular Solution - Breast Cancer | Phase 3 | Recruiting | Risen (Suzhou) Pharma Tech Co., Ltd. | 312 | 2025-11-12 | 2025-12-30 |
| PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer Fluzoparib, Dalpiciclib, Fulvestrant/AI - Breast Cancer Metastatic | Phase 3 | Active not recruiting | Zhimin Shao | 307 | 2024-09-01 | 2024-09-25 |
Breast Neoplasms (3) · Esophageal Squamous Cell Carcinoma (1)
Fujian Cancer Hospital (1) · Peking University Cancer Hospital & Institute (1) · Risen (Suzhou) Pharma Tech Co., Ltd. (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · Zhimin Shao (1)
China (4)
Xianming Luo, Doctor (1) · Ying Wang (1)